Congenital Malformation Clinical Trial
— PENEWOfficial title:
Congenital Malformations and Intrauterine Pollutants Exposure (Alcohol, Solvents and Pesticides) in Brittany. Population Based Case-control Study Short Title : Malformations and Environment Acronym : PENEW for "Pregnancy Environment and Newborn Malformations"
Verified date | May 2023 |
Source | Rennes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Congenital malformations rate is about 3% in France. There are already 5 registries in France, covering about 16% of French births: Paris Registry, (about 38 000 births /year), Alsace Registry, (about 23 000 births/year), Rhône-Alpes Registry, (about 56 000 births/year), Auvergne Registry, (about 14 000 births/year), and la Réunion Registry. The aim of malformation registries is to carry out epidemiologic surveillance of congenital anomalies. The objectives are mainly to provide essential epidemiologic information on congenital anomalies, to facilitate the early warning of teratogenic exposures, to act as an information and resource centre regarding clusters, to provide data for research related to the causes and prevention of congenital anomalies. A previous study was carried out in Brittany in 2008-2009, by the perinatal network of Ille et Vilaine, in collaboration with two research teams (Inserm U1085 and Inserm U 936), to record all cases of 4 types of congenital anomalies: congenital heart disease, spina bifida, diaphragmatic hernia and hypospadia. The results showed prevalence rates similar to those observed by Eurocat for spina bifida and diaphragmatic hernia, but a higher prevalence regarding congenital heart diseases and hypospadia. In this study the investigators could not determine whether this was due to a real higher frequency or to a particular exhaustiveness in the recording methodology. There are hypothesis about the role of intrauterine exposure to pesticides, known as endocrine disruptors, and the risk of congenital genital anomalies. Brittany is an intensive agricultural area, and it is thus worth studying the impact of pesticides exposure on congenital anomalies. There are also hypothesis on the impact of occupational exposure to solvents on congenital anomalies (Garlantezec 2009), and on the role of alcohol exposure (which concerns about 8% pregnant women in France) on oro-facial clefts and congenital heart diseases. The Registry of congenital anomalies in Brittany was set up in 2010. The main aim is to study the impact of intra-uterine exposure to solvents, pesticides and alcohol on the risk of congenital malformations diagnosed at births, by measuring the exposure both directly in meconium, and indirectly by questionnaires. Secondary objectives are to study other risk factors such as medicine intake, pregnancy illness…
Status | Completed |
Enrollment | 1657 |
Est. completion date | December 31, 2020 |
Est. primary completion date | December 31, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A to 12 Months |
Eligibility | Inclusion Criteria: All live births, fetal deaths with gestational age (GA) =22 weeks and terminations of pregnancy for medical reasons (IMG) from 20 weeks of amenorrhea (SA) included. - born from mothers living in Brittany at delivery - with a congenital anomaly according to Eurocat criteria, diagnosed or suspected (and then confirmed) at birth - or with mild congenital heart defects, genital anomalies or hip dislocation diagnosed after birth (and before the age of one) Suspicion of chromosomal abnormality or genetic syndrome on purely clinical criteria but not yet authenticated by genetic analyzes. If the chromosomal or genetic abnormalities are secondarily authenticated, these cases will be excluded a posteriori. Non inclusion criteria : - Spontaneous abortion before 22 weeks gestational age. - IMG before the 20 week term amenorrhea - Chromosomal abnormalities or syndromes genetic authenticated by karyotype or analysis in molecular biology, in antenatal - Mother with legal protection (guardianship) Exclusion Criteria: - Prenatally suspected malformations, which are not confirmed by postnatal screening or clinical evolution |
Country | Name | City | State |
---|---|---|---|
France | Brest University Hospital | Brest | Brittany |
France | Polyclinique de Keraudren | Brest | Brittany |
France | Lannion Hospital | Lannion | Brittany |
France | Lorient Hospital | Lorient | Brittany |
France | Ploermel Hospital | Ploermel | Brittany |
France | Quimper Hospital | Quimper | Brittany |
France | Rennes University Hospital | Rennes | Brittany |
France | Saint-Brieuc Hospital | Saint-Brieuc | Brittany |
France | Saint-Grégoire Hospital | Saint-Grégoire | Brittany |
France | Clinique Océane | Vannes | Brittany |
France | Vannes Hospital | Vannes | Brittany |
Lead Sponsor | Collaborator |
---|---|
Rennes University Hospital |
France,
Meyer-Monath M, Beaumont J, Morel I, Rouget F, Tack K, Lestremau F. Analysis of BTEX and chlorinated solvents in meconium by headspace-solid-phase microextraction gas chromatography coupled with mass spectrometry. Anal Bioanal Chem. 2014 Jul;406(18):4481-90. doi: 10.1007/s00216-014-7836-2. Epub 2014 May 18. — View Citation
Meyer-Monath M, Chatellier C, Cabooter D, Rouget F, Morel I, Lestremau F. Development of liquid chromatography methods coupled to mass spectrometry for the analysis of substances with a wide variety of polarity in meconium. Talanta. 2015 Jun 1;138:231-239. doi: 10.1016/j.talanta.2015.02.058. Epub 2015 Mar 19. — View Citation
Meyer-Monath M, Chatellier C, Rouget F, Morel I, Lestremau F. Development of a multi-residue method in a fetal matrix: analysis of meconium. Anal Bioanal Chem. 2014 Dec;406(30):7785-97. doi: 10.1007/s00216-014-8243-4. Epub 2014 Nov 9. — View Citation
Rouget F, Bihannic A, Cordier S, Multigner L, Meyer-Monath M, Mercier F, Pladys P, Garlantezec R. Petroleum and Chlorinated Solvents in Meconium and the Risk of Hypospadias: A Pilot Study. Front Pediatr. 2021 Jun 2;9:640064. doi: 10.3389/fped.2021.640064. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | impact of intra-uterine exposure to solvents, pesticides and alcohol on the risk of congenital malformations diagnosed at births, by measuring the exposure both directly in meconium, and indirectly by questionnaires. | impact of intra-uterine exposure to solvents, pesticides and alcohol on the risk of congenital malformations diagnosed at births, by measuring the exposure both directly in meconium, and indirectly by questionnaires. | up to 48 hours | |
Secondary | other risk factors such as medicine intake, pregnancy illness… | other risk factors such as medicine intake, pregnancy illness… | up to 48 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04150120 -
eHealth as an Aid for Facilitating and Supporting Self-management in Families With Long-term Childhood Illness
|
N/A | |
Completed |
NCT03984266 -
The Pilot Study of High-throughput Sequencing in Neonatal Birth Defects
|
||
Recruiting |
NCT02551081 -
Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units
|
||
Not yet recruiting |
NCT02607189 -
Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units
|
N/A | |
Recruiting |
NCT06252415 -
Evaluation of Rapid First-line Genome Sequencing for Prenatal Diagnosis of Congenital Malformations in Comparison With Chromosomal Microarray and Exome Sequencing
|
||
Recruiting |
NCT03476083 -
Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission
|
Phase 4 | |
Completed |
NCT05620056 -
A Population-based Study of Drug Exposures and Adverse Pregnancy Outcomes in China (DEEP)
|
||
Completed |
NCT05810545 -
Drinking Water PFAS, Pregnancy Outcome and Maternal Morbidity
|
||
Completed |
NCT03565822 -
The Impact of the Birth of a Child With a Rare Abdomino-thoracic Malformation
|
N/A | |
Completed |
NCT03799705 -
Genetic Variants in Nicotinamide Adenine Dinucleotide (NAD) Synthesis Pathway
|